Department of Obstetrics and Gynecology, Erciyes University Medicine Faculty, Kayseri, Turkey.
Department of Obstetrics and Gynecology, Kayseri City Hospital, Kayseri, Turkey.
Placenta. 2022 Jun 1;123:41-45. doi: 10.1016/j.placenta.2022.05.002. Epub 2022 May 5.
Considering that preeclampsia is characterized by oxidative stress, inflammation, and endothelial dysfunction, we hypothesized that preeclampsia and preeclampsia severity may affect the telomerase levels of the mother.
This cross-sectional case control study comprised 86 participants who were separated into three groups as severe preeclampsia, non-severe preeclampsia, and healthy control group. Venous blood samples were obtained from pregnant women with severe preeclampsia just before delivery for biochemical analysis and to evaluate maternal serum telomerase levels. Since gestational age, maternal age and BMI would have an effect on maternal serum telomerase levels, serum samples were taken in the control group and non-severe preeclampsia group at similar gestational age during clinical visits in order to homogenize these parameters, and these patients were followed up. Telomerase levels in maternal serum were evaluated using the enzyme-linked immune-sorbent assay.
Maternal age, nulliparity, body mass index (kg/m) at blood sampling day, ethnicity, smoking and history of caesarian section were statistically similar among the groups. The mean birth weight percentiles were the lowest in the severe preeclampsia group. Fetal growth restriction rates were significantly higher in the severe preeclampsia group than in the non-severe preeclampsia group. Gestational age at blood drawn was similar among groups. Neutrophil lymphocyte ratio, platelet lymphocyte ratio, mean platelet volume, red cell distribution width and white blood cell were statistically different among groups. The serum telomerase level was 1.137 ± 0.390 ng/mL in the severe preeclampsia group, 0.763 ± 0.390 ng/mL in the non-severe preeclampsia group, and 0.425 ± 0.160 ng/mL in the control group (p < .001).
This study indicated that maternal serum telomerase levels were significantly increased in both preeclampsia groups.
考虑到子痫前期的特征是氧化应激、炎症和内皮功能障碍，我们假设子痫前期及其严重程度可能会影响母亲的端粒酶水平。
这项横断面病例对照研究共纳入 86 名参与者，分为重度子痫前期组、非重度子痫前期组和健康对照组。重度子痫前期孕妇在分娩前采集静脉血进行生化分析和评估母体血清端粒酶水平。由于胎龄、母亲年龄和 BMI 会影响母体血清端粒酶水平，因此在临床就诊时在对照组和非重度子痫前期组采集相同胎龄的血清样本，以均匀这些参数，并对这些患者进行随访。使用酶联免疫吸附试验评估母体血清中端粒酶的水平。
各组间的母亲年龄、初产妇、采血日 BMI（kg/m）、种族、吸烟和剖宫产史无统计学差异。重度子痫前期组的平均出生体重百分位数最低。重度子痫前期组胎儿生长受限发生率明显高于非重度子痫前期组。采血时的胎龄在各组间相似。中性粒细胞淋巴细胞比、血小板淋巴细胞比、平均血小板体积、红细胞分布宽度和白细胞在各组间存在统计学差异。重度子痫前期组血清端粒酶水平为 1.137±0.390ng/mL，非重度子痫前期组为 0.763±0.390ng/mL，对照组为 0.425±0.160ng/mL（p<.001）。
本研究表明，子痫前期两组的母体血清端粒酶水平均显著升高。
